Additionally, TRAIL’s ability to selectively induce apoptosis in tumor cells has led to development of TRAIL-receptor agonist or recombinant TRAIL for use in cancer therapy [19], highlighting its potential not only as a biomarker but also as a therapeutic target to restore immune balance. This evidence concerns the gene TNFSF10 and neoplasm.